Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ACACA | Q13085 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4394852 | 1.00 | RAB9A (0.54) | RAB9AKMT2AMEN1KLK7ACACB | |
| SCHEMBL4012255 | 0.94 | ACACB (0.55) | RAB9AACACBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4012250 | 0.94 | ACACB (0.55) | RAB9AACACBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13590748 | 0.90 | ACACB (0.64) | RAB9AKMT2AMEN1ACACBACACA | |
| SCHEMBL4014320 | 0.87 | ACACB (0.58) | RAB9AACACBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4014311 | 0.87 | ACACB (0.58) | RAB9AACACBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4394883 | 0.86 | ACACB (0.55) | ACACBSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL4394891 | 0.86 | ACACB (0.55) | ACACBSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL4390600 | 0.85 | ACACB (0.53) | RAB9AKMT2AMEN1ACACBSMN1; SMN2 | |
| SCHEMBL4390608 | 0.85 | ACACB (0.53) | RAB9AKMT2AMEN1ACACBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | RAB9A 3450/4885KMT2A 1754/4885MEN1 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.